Latest Content

FDA cut required monitoring for tarlatamab’s first 2 doses from 22-24 hours to 6-8 hours, easing a barrier to community cancer care.

Endometriosis was found to nearly double absenteeism and work-ability impairment, according to one study.

Shiven B. Patel, MD, MBA, shares strategies for closing biomarker testing gaps, including among patients with non–small cell lung cancer.

The ESC's 2026 heart failure guidelines overhaul HF classification, rename therapy categories, and add a new HFpEF recommendation.

Francesca Polverino, MD, PhD, discusses COPD biomarkers, patient susceptibility, overtreatment risk, and the future of risk stratification.

The FDA cleared PrecivityAD2, a blood test from C2N Diagnostics that helps diagnose Alzheimer disease in adults as young as 40.

Reference countries have limited room to simply raise their own drug budgets to absorb the pressure, the lead study author explains.

An independent review of BTK inhibitors in mantle cell lymphoma finds areas are of strength both second-generation therapies, as authors call for clinical trials to inform guidelines.

Five August FDA approvals introduced novel therapies across vaccines, neurology, oncology, myeloma, and dermatomyositis, despite some regulatory pushback.